CMC-Fb-002
CMCi010-A
General#
Cell Line |
|
| hPSCreg Name | CMCi010-A |
| Alternative name(s) |
CMC-Fb-002
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Last update | 4th March 2021 |
| User feedback | |
Provider |
|
| Generator | Catholic University of Korea (CMC) |
| Owner | Catholic University of Korea (CMC) |
External Databases |
|
| BioSamples | SAMEA7807674 |
| CLO | CLO_0103129 |
| Cellosaurus | CVCL_A4EV |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information#
General Donor Information |
|
| Sex | female |
| Ethnicity | Asian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46 XX
|
External Databases (Donor) |
|
| BioSamples | SAMEA8359740 |
Ethics#
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Provide contact information of the holder of the original Donor Information Sheet: | cttailor@catholic.ac.kr |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Contact information / weblink | cttailor@catholic.ac.kr |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | |
| Approval number | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | |
| Approval number | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation#
General |
|
| Source cell line name |
peripheral blood monouclear cells Derived from same source line (potentially other lot and donor, see below):
|
| Source cell type |
Peripheral blood mononuclear cellSynonyms
|
Reprogramming method |
|
| Vector type | None |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions#
| Surface coating | Matrigel/Geltrex | ||||||
| Feeder cells |
No |
||||||
| Medium |
mTeSR™ 1
Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Morphology pictures
Differentiation Potency
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.